文献速递脑血管病

妊娠及产后早期急性缺血性卒中的血管内取栓治疗

Endovascular Thrombectomy for Treatment of Acute Ischemic Stroke During Pregnancy and the Early Postpartum Period.
PubMed 文献 · Stroke · 2021-09-20

基于美国全国住院患者样本2012-2018年数据,4590例妊娠及产后急性缺血性卒中患者中180例(3.9%)接受机械取栓,取栓使用率在2015-2018年增至5.3%。与非妊娠取栓患者相比,妊娠/产后患者颅内出血率较低(11%对24%),出院时不良功能结局率较低(50%对72%)。倾向评分匹配后,取栓与药物治疗在功能结局和住院时长上无差异,取栓组无院内死亡或流产。

要点

  • 妊娠及产后急性缺血性卒中取栓使用率从2015年前的1.9%升至2015-2018年的5.3%。
  • 妊娠/产后取栓患者颅内出血风险独立降低(aOR 0.26,95%CI 0.09-0.70)。
  • 取栓与药物治疗相比功能结局无差异,但静脉血栓栓塞更常见(17%对0%)。

核心结论

  • 基于全国索赔数据的大规模分析提示,机械取栓是妊娠及产后急性缺血性卒中的安全有效治疗。

研究设计与样本

  • 回顾性横断面分析,查询美国全国住院患者样本(2012-2018年),纳入4590例妊娠及产后(产后6周内)急性缺血性卒中患者,其中180例(3.9%)接受机械取栓。
  • 采用复杂抽样回归模型评估校正关联,并用倾向评分匹配处理适应证混杂。

主要发现

  • 取栓使用率在2015-2018年临床试验时代后上升(1.9%对5.3%,P=0.011)。
  • 与非妊娠取栓患者相比,妊娠/产后患者颅内出血率较低(11%对24%,P=0.069),出院时不良功能结局率较低(50%对72%,P=0.003)。
  • 多变量分析校正年龄、病情严重度和卒中严重度后,妊娠/产后状态与颅内出血风险降低独立相关(aOR 0.26,95%CI 0.09-0.70,P=0.008)。
  • 倾向评分匹配后,取栓组与药物治疗组静脉血栓栓塞频率(17%对0%,P=0.001)和妊娠相关并发症(44%对64%,P=0.034)不同,但出院功能结局和住院时长无差异。
  • 取栓的妊娠/产后患者住院期间无死亡或流产。

临床怎么用

  • 对于妊娠及产后早期急性缺血性卒中患者,机械取栓可考虑作为治疗选择,需结合多学科评估。

局限性

  • 缺乏前瞻性临床试验数据,结论基于全国索赔数据的回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Acute ischemic stroke (AIS) is a rare occurrence during pregnancy and the postpartum period. Existing literature evaluating endovascular mechanical thrombectomy (MT) for this patient population is limited. METHODS: The National Inpatient Sample was queried from 2012 to 2018 to identify and characterize pregnant and postpartum patients (up to 6 weeks following childbirth) with AIS treated with MT. Complications and outcomes were compared with nonpregnant female patients treated with MT and to other pregnant and postpartum patients managed medically. Complex samples regression models and propensity score matching were implemented to assess adjusted associations and to address confounding by indication, respectively. RESULTS: Among 4590 pregnant and postpartum patients with AIS, 180 (3.9%) were treated with MT, and rates of utilization increased following the MT clinical trial era (2015-2018; 1.9% versus 5.3%, P=0.011). Compared with nonpregnant patients with AIS treated with MT, they experienced lower rates of intracranial hemorrhage (11% versus 24%, P=0.069) and poor functional outcome (50% versus 72%, P=0.003) at discharge. Pregnant/postpartum status was independently associated with a lower likelihood of development of intracranial hemorrhage (adjusted odds ratio, 0.26 [95% CI, 0.09-0.70]; P=0.008) following multivariable analysis adjusting for age, illness severity, and stroke severity. Following propensity score matching, pregnant and postpartum patients treated with MT and those medically managed differed in frequency of venous thromboembolism (17% versus 0%, P=0.001) and complications related to pregnancy (44% versus 64%, P=0.034), but not in functional outcome at discharge or hospital length of stay. Pregnant and postpartum women treated with MT did not experience mortality or miscarriage during hospitalization. CONCLUSIONS: This large-scale analysis utilizing national claims data suggests that MT is a safe and efficacious therapy for AIS during pregnancy and the postpartum period. In the absence of prospective clinical trials, population-based cross-sectional analyses such as the present study provide valuable clinical insight.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Dicpinigaitis AJ, Sursal T, Morse CA, et al. Endovascular Thrombectomy for Treatment of Acute Ischemic Stroke During Pregnancy and the Early Postpartum Period. Stroke. 2021. PMID: 34538088. doi:10.1161/STROKEAHA.121.034303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。